Cargando…

Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy

SIMPLE SUMMARY: Localized ablation is an emerging treatment for prostate cancer that minimizes recovery time and improves functional retention. However, standard histological processing of diagnostic prostate biopsies is currently performed too late to inform the treatment of localized lesions at th...

Descripción completa

Detalles Bibliográficos
Autores principales: Behr, Madeline R., Halat, Shams K., Sholl, Andrew B., Krane, Louis Spencer, Brown, Jonathan Quincy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913800/
https://www.ncbi.nlm.nih.gov/pubmed/36765751
http://dx.doi.org/10.3390/cancers15030792
_version_ 1784885515459231744
author Behr, Madeline R.
Halat, Shams K.
Sholl, Andrew B.
Krane, Louis Spencer
Brown, Jonathan Quincy
author_facet Behr, Madeline R.
Halat, Shams K.
Sholl, Andrew B.
Krane, Louis Spencer
Brown, Jonathan Quincy
author_sort Behr, Madeline R.
collection PubMed
description SIMPLE SUMMARY: Localized ablation is an emerging treatment for prostate cancer that minimizes recovery time and improves functional retention. However, standard histological processing of diagnostic prostate biopsies is currently performed too late to inform the treatment of localized lesions at the time of the diagnostic biopsy procedure. We investigated the feasibility of structured illumination microscopy (SIM) as an adjunct tool to confirm malignancy in fresh prostate biopsies for a future “see-and-treat” paradigm of localized prostate cancer. Forty-six biopsies were assessed by two pathologists, resulting in 92% and 87% overall diagnostic accuracies, respectively. In a proposed “clinical decision tree”, urologist predictions from MRI fusion images were compared to diagnoses from SIM images, which demonstrated that SIM feedback would constructively inform on-site intervention of localized prostate cancer and confirm margins. We demonstrated that the process necessary to generate and diagnose pseudo-hematoxylin and eosin biopsy images via SIM can be achieved in well under 15 minutes. ABSTRACT: Prostate cancer continues to be the most diagnosed non-skin malignancy in men. While up to one in eight men will be diagnosed in their lifetimes, most diagnoses are not fatal. Better lesion location accuracy combined with emerging localized treatment methods are increasingly being utilized as a treatment option to preserve healthy function in eligible patients. In locating lesions which are generally <2cc within a prostate (average size 45cc), small variance in MRI-determined boundaries, tumoral heterogeneity, patient characteristics including location of lesion and prostatic calcifications, and patient motion during the procedure can inhibit accurate sampling for diagnosis. The locations of biopsies are recorded and are then fully processed by histology and diagnosed via pathology, often days to weeks later. Utilization of real-time feedback could improve accuracy, potentially prevent repeat procedures, and allow patients to undergo treatment of clinically localized disease at earlier stages. Unfortunately, there is currently no reliable real-time feedback process for confirming diagnosis of biopsy samples. We examined the feasibility of implementing structured illumination microscopy (SIM) as a method for on-site diagnostic biopsy imaging to potentially combine the diagnostic and treatment appointments for prostate cancer patients, or to confirm tumoral margins for localized ablation procedures. We imaged biopsies from 39 patients undergoing image-guided diagnostic biopsy using a customized SIM system and a dual-color fluorescent hematoxylin & eosin (H&E) analog. The biopsy images had an average size of 342 megapixels (minimum 78.1, maximum 842) and an average imaging duration of 145 s (minimum 56, maximum 322). Comparison of urologist’s suspicion of malignancy based on MRI, to pathologist diagnosis of biopsy images obtained in real time, reveals that real-time biopsy imaging could significantly improve confirmation of malignancy or tumoral margins over medical imaging alone.
format Online
Article
Text
id pubmed-9913800
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99138002023-02-11 Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy Behr, Madeline R. Halat, Shams K. Sholl, Andrew B. Krane, Louis Spencer Brown, Jonathan Quincy Cancers (Basel) Article SIMPLE SUMMARY: Localized ablation is an emerging treatment for prostate cancer that minimizes recovery time and improves functional retention. However, standard histological processing of diagnostic prostate biopsies is currently performed too late to inform the treatment of localized lesions at the time of the diagnostic biopsy procedure. We investigated the feasibility of structured illumination microscopy (SIM) as an adjunct tool to confirm malignancy in fresh prostate biopsies for a future “see-and-treat” paradigm of localized prostate cancer. Forty-six biopsies were assessed by two pathologists, resulting in 92% and 87% overall diagnostic accuracies, respectively. In a proposed “clinical decision tree”, urologist predictions from MRI fusion images were compared to diagnoses from SIM images, which demonstrated that SIM feedback would constructively inform on-site intervention of localized prostate cancer and confirm margins. We demonstrated that the process necessary to generate and diagnose pseudo-hematoxylin and eosin biopsy images via SIM can be achieved in well under 15 minutes. ABSTRACT: Prostate cancer continues to be the most diagnosed non-skin malignancy in men. While up to one in eight men will be diagnosed in their lifetimes, most diagnoses are not fatal. Better lesion location accuracy combined with emerging localized treatment methods are increasingly being utilized as a treatment option to preserve healthy function in eligible patients. In locating lesions which are generally <2cc within a prostate (average size 45cc), small variance in MRI-determined boundaries, tumoral heterogeneity, patient characteristics including location of lesion and prostatic calcifications, and patient motion during the procedure can inhibit accurate sampling for diagnosis. The locations of biopsies are recorded and are then fully processed by histology and diagnosed via pathology, often days to weeks later. Utilization of real-time feedback could improve accuracy, potentially prevent repeat procedures, and allow patients to undergo treatment of clinically localized disease at earlier stages. Unfortunately, there is currently no reliable real-time feedback process for confirming diagnosis of biopsy samples. We examined the feasibility of implementing structured illumination microscopy (SIM) as a method for on-site diagnostic biopsy imaging to potentially combine the diagnostic and treatment appointments for prostate cancer patients, or to confirm tumoral margins for localized ablation procedures. We imaged biopsies from 39 patients undergoing image-guided diagnostic biopsy using a customized SIM system and a dual-color fluorescent hematoxylin & eosin (H&E) analog. The biopsy images had an average size of 342 megapixels (minimum 78.1, maximum 842) and an average imaging duration of 145 s (minimum 56, maximum 322). Comparison of urologist’s suspicion of malignancy based on MRI, to pathologist diagnosis of biopsy images obtained in real time, reveals that real-time biopsy imaging could significantly improve confirmation of malignancy or tumoral margins over medical imaging alone. MDPI 2023-01-27 /pmc/articles/PMC9913800/ /pubmed/36765751 http://dx.doi.org/10.3390/cancers15030792 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Behr, Madeline R.
Halat, Shams K.
Sholl, Andrew B.
Krane, Louis Spencer
Brown, Jonathan Quincy
Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy
title Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy
title_full Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy
title_fullStr Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy
title_full_unstemmed Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy
title_short Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-And-Treat Guidance of Localized Prostate Cancer Therapy
title_sort rapid on-site microscopy and mapping of diagnostic biopsies for see-and-treat guidance of localized prostate cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913800/
https://www.ncbi.nlm.nih.gov/pubmed/36765751
http://dx.doi.org/10.3390/cancers15030792
work_keys_str_mv AT behrmadeliner rapidonsitemicroscopyandmappingofdiagnosticbiopsiesforseeandtreatguidanceoflocalizedprostatecancertherapy
AT halatshamsk rapidonsitemicroscopyandmappingofdiagnosticbiopsiesforseeandtreatguidanceoflocalizedprostatecancertherapy
AT shollandrewb rapidonsitemicroscopyandmappingofdiagnosticbiopsiesforseeandtreatguidanceoflocalizedprostatecancertherapy
AT kranelouisspencer rapidonsitemicroscopyandmappingofdiagnosticbiopsiesforseeandtreatguidanceoflocalizedprostatecancertherapy
AT brownjonathanquincy rapidonsitemicroscopyandmappingofdiagnosticbiopsiesforseeandtreatguidanceoflocalizedprostatecancertherapy